otx015
Nut Midline Carcinoma
Merck Sharp & Dohme LLCPhase 1Dormant
C
34/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 19/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Nut Midline Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cudc-907 Curis, Inc. | Phase 1 | CC |
Bet Bromodomain Inhibitor Zen-3694 National Cancer Institute (NCI) | Phase 1 | CC |
Molibresib GlaxoSmithKline | Phase 1 | CC |
Abemaciclib National Cancer Institute (NCI) | Phase 1 | CC |
ep31670 Epigenetix, Inc. | Phase 1 | CC |
mt-4561 Tanabe Pharma America, Inc. | Phase 1/2 | NR |
Same molecule, other indications
otx015 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →